About Algorithmic Biologics
Algorithmic Biologics focuses on molecular diagnostics and discovery through technology in the biotech sector. Their main offerings include a software platform with molecular testing workflows to improve efficiency and accuracy, leveraging AI and molecular computing research. The company primarily serves the healthcare industry, particularly in the areas of genomics research and clinical diagnostics. It was founded in 2021 and is based in Bangaluru, India.
Algorithmic Biologics's Product Videos
Algorithmic Biologics's Products & Differentiators
Tapestry is a SaaS software for genomic testing that can search DNA/RNA of interest in large number of sample. It works across sample types and genomic testing platforms like RT-PCR, Next-generation sequencing etc. It can deliver up to 10X gains with software alone and no additional CapEx investment. The patented technology behind Tapestry works at the intersection of computational mathematics and molecular science, leveraging principles from coding-decoding to reduce the amount of tests needed to deliver large number of results. It has been published in leading scientific publications and shown concordant results in multiple clinical trials conducted at prestigious research institutes. The solution is CE certified and commercially available.
Algorithmic Biologics Patents
Algorithmic Biologics has filed 3 patents.
Severe acute respiratory syndrome, Betacoronaviruses, Animal viral diseases, Coronaviridae, Molecular biology
Severe acute respiratory syndrome, Betacoronaviruses, Animal viral diseases, Coronaviridae, Molecular biology
Latest Algorithmic Biologics News
Feb 5, 2024
Get latest articles and stories on Business at LatestLY. New Delhi [India], February 5: Deeptech startup Algorithmic Biologics (AlgoBio), leveraging advanced algorithms and AI to revolutionize molecular testing efficiency and scale, unveiled the Tapestry platform for next-generation sequencing (NGS) at Genomics India Conference 2024 today. Aligned with the company's vision of enabling accurate and affordable large-scale molecular testing, Tapestry empowers genomics labs to cut sequencing costs significantly by eliminating 60 per cent to 90 per cent of library preparation costs that is 33 per cent-50 per cent of the total sequencing costs. Founded by Dr Manoj Gopalkrishnan - a multi-disciplinary technologist and professor at IIT Bombay - AlgoBio also announced securing USD 2.5 million in pre-series A funding led by Bharat innovation Fund (BIF) ventures with participation from existing investor Axilor Ventures. SRV Media New Delhi [India], February 5: Deeptech startup Algorithmic Biologics (AlgoBio), leveraging advanced algorithms and AI to revolutionize molecular testing efficiency and scale, unveiled the Tapestry platform for next-generation sequencing (NGS) at Genomics India Conference 2024 today. Aligned with the company's vision of enabling accurate and affordable large-scale molecular testing, Tapestry empowers genomics labs to cut sequencing costs significantly by eliminating 60 per cent to 90 per cent of library preparation costs that is 33 per cent-50 per cent of the total sequencing costs. Founded by Dr Manoj Gopalkrishnan - a multi-disciplinary technologist and professor at IIT Bombay - AlgoBio also announced securing USD 2.5 million in pre-series A funding led by Bharat innovation Fund (BIF) ventures with participation from existing investor Axilor Ventures. Proceeds of the fundraise will be used to support the product pipeline, building the sales organization and furthering their international expansion. "Tapestry is providing affordable genomics sequencing for all, in collaboration with leading genomics labs," said Dr Manoj Gopalkrishnan the founder and CEO of Algorithmic Biologics. "We are very glad to have BIF join us as an investor and to have continued support of Axilor. We are excited to learn from their expertise at helping deeptech companies achieve transformation throughout India as well as internationally." "Molecular diagnostics is an indispensable tool in the biotech field, contributing to advancements in healthcare through early disease diagnosis, mass population testing and enabling personalized medicine. We are glad to support AlgoBio in democratizing access to molecular tests through their innovative Tapestry Platform" said Som Pal Choudhury, co-founder and partner at BIF. "Our continued investment in AlgoBio aligns with our commitment to support visionary innovators with technology ideas that can reshape industries." said Nidhi Mathur, Venture Partner at Axilor Ventures. "The company has developed unique algorithmic approaches previously unavailable to the genomics universe allowing them to achieve 10x efficiencies with existing infrastructure." AlgoBio has recently partnered with Dhiti Omics Technologies, one of the pioneers of molecular diagnostics services in India to offer 'Focused Exome Sequencing' powered by Tapestry. "Tapestry by AlgoBio isn't merely a solution; it's an initiative to lead a future where everyone can access the transformative capabilities of NGS, propelling scientific progress while prioritizing precision. We are thrilled to partner with AlgoBio to bring affordable genomic testing to every deserving patient. ", added Dr Sudha, co-founder and executive director of Dhiti Omics. Tapestry is a CE certified technology that has been widely spotlighted in international scientific news publications, and clinically validated with reputed research institutes. It was used extensively for affordable Covid testing using RT-PCR. It has since been extended to other molecular tests like NAAT (used for blood testing for HIV, etc), Mass Spectrometry (used for tests like Newborn Screening), and now NGS to enable further applications like rare disease diagnosis, tumor cell sequencing, etc. Next-generation sequencing (NGS) revolutionized biology by enabling fast, accurate DNA/RNA sequencing. This unlocks deep insights into genes, impacting areas like diagnosing rare diseases, studying tumors and investigating cellular biology. Despite being transformative, NGS cost remained a barrier to wider use. At the turn of the century, the first human genome was sequenced at the price tag of USD 2.7 Billion. Over the next two decades, this price point has come down to 0.00001 per cent of that but it still remains out of reach for most of us. However, recent advancements like compressed sensing technology from AlgoBio are dramatically lowering costs, bringing NGS closer to routine checkups. This shift holds immense potential for personalized medicine and improved healthcare. Algorithmic Biologics (AlgoBio) pioneers novel solutions at the frontier of molecular science and computational algorithms. Leveraging its patented Tapestry platform which is based on molecular computing and artificial intelligence (AI), AlgoBio empowers large-scale molecular testing with unprecedented efficiency and accuracy. Tapestry seamlessly integrates with industry-standard NGS workflows significantly reducing time, resource, and cost burdens. Through an innovative information multiplexing platform, Tapestry delivers cost savings of up to 90 per cent in library preparation, a critical bottleneck in NGS pipelines. Drawing inspiration from data compression techniques, Tapestry "zips" molecular information in the test tube itself leading to dramatic efficiencies in library preparation. AlgoBio's Tapestry platform represents a paradigm shift in molecular testing by unlocking significant cost efficiencies, democratizing access to sequencing and expanding diagnostic horizons. To learn more about Algorithmic Biologics, visit www.algorithmicbiologics.com (ADVERTORIAL DISCLAIMER: The above press release has been provided by SRV Media. ANI will not be responsible in any way for the content of the same) (This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)
Algorithmic Biologics Frequently Asked Questions (FAQ)
When was Algorithmic Biologics founded?
Algorithmic Biologics was founded in 2021.
Where is Algorithmic Biologics's headquarters?
Algorithmic Biologics's headquarters is located at 363/364, 8th Main Road, Bengaluru.
What is Algorithmic Biologics's latest funding round?
Algorithmic Biologics's latest funding round is Seed VC - II.
How much did Algorithmic Biologics raise?
Algorithmic Biologics raised a total of $2.5M.
Who are the investors of Algorithmic Biologics?
Investors of Algorithmic Biologics include Axilor Ventures, Bharat Fund and Google for Startups Accelerator.
Who are Algorithmic Biologics's competitors?
Competitors of Algorithmic Biologics include Iambic Therapeutics and 2 more.
What products does Algorithmic Biologics offer?
Algorithmic Biologics's products include Tapestry.
Compare Algorithmic Biologics to Competitors
Everist Health (formerly Everist Genomics and Genetics Squared) is a personalized medicine company which develops and commercializes medically unique diagnostics, prognostics and therapeutic selection technologies. Through their tools, the company seeks to help physicians improve medical outcomes and reduce the total cost of care. EGI's products integrate with mobile digital services, smartphones, and tablet computers resulting in advanced medical technology.
Singleron Biotechnologies operates as a biotechnology company. It focuses on applying single-cell analysis technologies. The company offers a comprehensive solution for single-cell multi-omics sequencing, which allows for novel approaches in clinical research and molecular diagnostics. Singleron primarily serves the healthcare industry, particularly in areas of clinical diagnosis, drug development, and health management. It was founded in 2018 and is based in Koln, Germany.
SeekGene specializes in single-cell sequencing and TCR-pMHC pairing technologies in understanding immune responses in the single-cell resolution to help screen, treat and monitor diseases.
Basepair is a bioinformatics company operating in the healthcare and technology sectors. The company provides a next-generation data analysis platform for Next-Generation Sequencing (NGS), offering services such as RNA-Seq Analysis, ChIP-Seq Analysis, DNA-Seq Analysis, and ATAC-Seq Analysis. Basepair primarily serves academic researchers, clinical laboratories, library prep kit manufacturers, R&D teams, and sequencing service providers. It was founded in 2015 and is based in New York, New York.
Axela is delivering on its mission to provide a simple and effective approach to personalized medicine by exploiting the dotLab System in research markets today to generate tomorrow's diagnostics. This strategy of offering a common technology platform to both markets aims to provide a opportunity to capitalize on discoveries. The approach has already resulted in applications with the potential to address segments of the large, underserved markets of oncology and cardiology that will be the focus of two funded clinical trials this summer and growing installed customer base. For a time these leading clinical researchers can use the direct understanding of protein interactions to develop quantitative assays on a single platform. dot technology has shortened the transition from protein discovery to application. The ability to measure biomolecular complexes in real-time aims to provide for new approaches to disease management.
Molecular Testing Labs operates as a health science company specializing in precision laboratory diagnostics within the healthcare industry. The company offers a range of services including high-complexity molecular testing, infectious disease testing, toxicology, and more. It primarily serves clinics, digital health companies, public health departments, and research universities. It was founded in 2011 and is based in Vancouver, Washington.